Wedbush Reiterates “Outperform” Rating for Avalo Therapeutics (NASDAQ:AVTX)

Wedbush restated their outperform rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report published on Thursday morning,RTT News reports. They currently have a $18.00 price objective on the stock. Wedbush also issued estimates for Avalo Therapeutics’ Q1 2025 earnings at $0.63 EPS.

A number of other equities analysts have also recently commented on AVTX. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. BTIG Research assumed coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Avalo Therapeutics Price Performance

AVTX stock opened at $7.66 on Thursday. Avalo Therapeutics has a one year low of $4.60 and a one year high of $34.46. The firm has a 50 day simple moving average of $7.45 and a two-hundred day simple moving average of $9.12.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP purchased a new stake in Avalo Therapeutics during the 4th quarter valued at about $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics during the 4th quarter worth approximately $145,000. Northern Trust Corp bought a new position in Avalo Therapeutics during the 4th quarter worth approximately $168,000. Finally, Bank of Montreal Can bought a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $446,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.